Serum basic fibroblast growth factor in men with and without prostate carcinoma

Area of Science:

• Oncology
• Biochemistry
• Medical Diagnostics

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth.
• Increased vascularity in prostate cancer is linked to disease stage and prognosis.
• Basic fibroblast growth factor (bFGF), an angiogenic inducer, is present in malignant prostate tissue.

Purpose of the Study:

• To investigate serum bFGF levels in men with and without prostate cancer.
• To determine if serum bFGF can serve as a diagnostic marker for prostate cancer.

Main Methods:

• Serum bFGF levels were measured using an enzyme-linked immunosorbent assay (ELISA).
• Archival serum samples from prostate cancer patients and control subjects were analyzed.
• Prostate volume was assessed via transrectal ultrasound.

Main Results:

• Serum bFGF levels were significantly higher in men with prostate carcinoma (P < 0.0007).
• In men with serum PSA < 4.0 ng/ml, bFGF levels were associated with carcinoma (P = 0.008).
• bFGF demonstrated 83% sensitivity and 44% specificity for detecting prostate cancer in this subgroup.

Conclusions:

• Serum bFGF levels are elevated in the majority of men diagnosed with prostate carcinoma.
• Elevated bFGF in men with normal PSA levels suggests potential diagnostic utility.
• Further research may explore bFGF's role in prostate cancer diagnosis and management.